Rural community decides if it should trust outside investor with bankrupt hospital

Independent hospitals can survive, but they face myriad challenges, many associated with the economies of scale.

Kaiser Health News reports on one facility—a 26-bed hospital in Surprise Valley, California—that is $4 million in debt—and in desperate need of outside help. The community may have found reason for hope, in the form of a 34-year-old former bodybuilder named Beau Gertz. He’s proposing a plan to use telemedicine to help boost revenue.

“If you do it correctly, there is a nice profit margin,” he said in an interview with Kaiser Health News, “There [are] extra visits you can get from telemedicine but … it has to be billed correctly, and it can’t be abused.”

Gertz says he will cover the seven-figure debt, though locals have heard a similar pitch before. Last year, the hospital board brought in an outside management company that “abandoned” the facility after just a few months.

Despite the skepticism, the 1,500 residents will vote Tuesday, June 5, whether to allow Gertz to buy the public hospital.

For the full story, visit the link below:

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.